Why the study?
To provide comprehensive guidance from the Anticoagulation Forum regarding the use of specific and non-specific direct oral anticoagulant reversal agents.
This document provides comprehensive guidance from the Anticoagulation Forum on the appropriate use, administration, and stewardship of DOAC reversal agents.
Provides actionable DOAC reversal protocols for clinicians; extends prior consensus with integrated stewardship guidance.
Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban and rivaroxaban reversal. Non-specific prohemostatic agents such as prothrombin complex concentrate (PCC) and activated PCC have also been used for DOAC reversal. The goal of this document is to provide comprehensive guidance from the Anticoagulation Forum, a North American organization of anticoagulation providers, regarding use of DOAC reversal agents. We discuss indications for reversal, provide guidance on how the individual reversal agents should be administered, and offer suggestions for stewardship at the health system level.
No takes yet. Share an insight, caveat, or question.
Cuker et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: